Advinus looks to license diabetes product; Seattle Genetics expecting big 2010;

 @FierceBiotech: VCs shell out $39M for Complete Genomics. Article | Follow @FierceBiotech 

> Now that its type II diabetes-treating molecule has finished initial trials, Advinus Therapeutics is pushing for Phase II trials and may license out the molecule to other drugmakers. Advinus has high hopes for the molecule, CEO Rashmi Barbhaiya told India Times. So far, the drug seems to have higher efficacy and safety than other drugs on the market. Story

> As Seattle Genetics awaits results from three key leukemia and lymphoma trials, analysts believe 2010 will be a big year for the company. Item

> Cibus Global, a San Diego-based company, has secured $1.2 million in funding out of a targeted $2.6 million. The funding will be used to further crop biotechnology. Article

> Sigmapharm Laboratories has applied to manufacture a generic version of Gilead Sciences' hepatits B drug, Hepsera. Gilead has 45 days to file a patent infringement suit against Sigmapharm, who alleged two of the company's patents are unenforceable. News

And Finally... Though GHB is more commonly known as a leading date-rape drug, it's also being considered as a fibromyalgia treatment. Jazz Pharmaceuticals has approached the FDA about selling GHB under the name Rekinla. The main concern: keeping it out of the hands of potential rapists. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.